Shares of Celyad SA (NASDAQ:CYAD) reached a new 52-week high on Thursday . The stock traded as high as $54.80 and last traded at $54.80, with a volume of 495 shares trading hands. The stock had previously closed at $53.50.

Several research firms recently weighed in on CYAD. Piper Jaffray Companies restated a “buy” rating and issued a $49.00 price objective (up from $35.00) on shares of Celyad SA in a report on Friday, September 1st. BidaskClub downgraded Celyad SA from a “buy” rating to a “hold” rating in a report on Tuesday, July 11th. Finally, ValuEngine upgraded Celyad SA from a “sell” rating to a “hold” rating in a report on Thursday, June 29th.

The firm’s 50 day moving average is $52.38 and its 200-day moving average is $52.38. The stock’s market capitalization is $545.78 million.

An institutional investor recently raised its position in Celyad SA stock. Victory Capital Management Inc. boosted its position in shares of Celyad SA (NASDAQ:CYAD) by 6.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 374,493 shares of the company’s stock after acquiring an additional 22,600 shares during the quarter. Victory Capital Management Inc. owned 3.93% of Celyad SA worth $9,988,000 at the end of the most recent quarter. 4.06% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at

Celyad SA Company Profile

Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company’s product, C-Cure, allows the differentiation of a patient’s own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle.

Receive News & Ratings for Celyad SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad SA and related companies with's FREE daily email newsletter.